Interleukin-17A-mediated psoriasis and cardiovascular comorbidities
- VernacularTitle:白细胞介素17A介导银屑病及心血管合并症的研究进展
- Author:
Ying ZHAO
1
;
Juanjuan WANG
;
Jiang JI
;
Wenxing SU
;
Yuqian WEI
;
Hong LENG
;
Yujie DING
;
Xin SHI
Author Information
- Keywords: Psoriasis; Interleukin-17; Cardiovascular diseases; Comorbidity; Interleukin-17A
- From: Chinese Journal of Dermatology 2022;55(1):76-79
- CountryChina
- Language:Chinese
- Abstract: The interleukin (IL) -23/IL-17 axis is the main pathway in the pathogenesis of plaque-type psoriasis vulgaris, and IL-17A plays a key role in the relevant immune pathways. IL-17A mediates overlapping inflammatory pathways in atherosclerosis and psoriasis, promotes inflammation, coagulation and thrombosis, and plays an important role in the occurrence and development of cardiovascular comorbidities in patients with psoriasis. Inhibiting the inflammatory effect of IL-17A can reduce the incidence and mortality of cardiovascular comorbidities in patients with severe psoriasis. This review summarizes recent research progress in IL-17A-mediated systemic inflammation and cardiovascular comorbidities in patients with psoriasis, and provides a reference for prevention and reduction of cardiovascular comorbidities in patients with psoriasis in clinical practice.
